Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Active not recruiting 10Recruiting 9Completed 8Unknown 3Terminated 3Withdrawn 2Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3

Interventions

Cisplatin 352Oxaliplatin 262Capecitabine 258Radiotherapy 240Gemcitabine 223Docetaxel 223Carboplatin 223Drug Therapy 219Cyclophosphamide 219Paclitaxel 205apatinib 201Bevacizumab 196camrelizumab 190Fluorouracil 188sintilimab 133Irinotecan 125Blood Specimen Collection 125Dexamethasone 123Etoposide 119Radiosurgery 118toripalimab 117Surgical Procedures, Operative 115pembrolizumab 112Pemetrexed 108anlotinib 105S 1 (combination) 105Leucovorin 102Surveys and Questionnaires 101Nivolumab 98tislelizumab 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × OTHER × luprolide acetate gel depot × Clear all
NCT04239599 2022-09-29

RCT-PHART2

Sunnybrook Health Sciences Centre

Phase NA Unknown
178 enrolled
Genitourinary

Prostatic Neoplasms

NCT03380806 2020-06-04

PBS

Juravinski Cancer Center

Phase 2 Unknown
100 enrolled
Genitourinary

Prostatic Neoplasms

NCT00452556 2014-03-19

The ELDORADO (Eligard®, Docetaxel and Radiotherapy) Study

Nova Scotia Cancer Centre

Phase 2 Unknown
86 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡